Clinical Analysis Of Different Doses Of Atorvastatin Calcium Tablets On Cerebral Vascular Interventional Therapy In Patients With Ischemic Cerebrovascular Disease

Objective: To analyze the clinical efficacy of different doses of Atorvastatin calcium tablets on cerebral vascular interventional therapy in patients with ischemic cerebrovascular disease. Methods: A total of 110 patients whose ischemic cerebrovascular diseases were treated with cerebral vascular interventional therapy in Daqing Oilfield General Hospital from October 2015 to October 2017 were randomized to the experimental group (n=55) and the control group (n=55). The control group was given 20 mg Atorvastatin calcium tablets three days before the administration of contrast agent and after cerebrovascular interventional therapy while the experimental group was given 80 mg Atorvastatin calcium tablets three days before the contrast media were used and 40 mg Atorvastatin calcium tablets after cerebrovascular interventional treatment. The incidence of contrast induced nephropathy (CIN), blood lipids, liver function, renal function, and hs-CRP level were compared between the two groups. Results: There were no significant differences between the two groups in the incidence of CIN, the serum levels of ALT, AST, LDL-C, HDL-C, TG, and TC at postoperative 24 and 72 hours respectively, and hs-CRP, Cys-C, beta 2-MG, Ccr, BUM, and Scr at preoperative 24 hours (all P>0.05). Compared with the control group, the experimental group showed lower hs-CRP, Cys-C, beta 2-MG, BUM, Scr at postoperative 72 hours. Compared with the control group, the experimental group demonstrated higher Ccr at postoperative 72 hours (all P<0.05). Conclusion: A higher dose of Atorvastatin calcium tablets can effectively improve the renal function after cerebral vascular interventional therapy in patients with ischemic cerebrovascular disease, and reduce the incidence of CIN, which is safer and worthy of reference.